Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy

Ou, Wenquan; Thapa, Raj Kumar; Jiang, Liyuan; Soe, Zar Chi; Gautam, Milan; Chang, Jae‐Hoon; Jeong, Jee–Heon; Ku, Sae Kwang; Choi, Han‐Gon; Yong, Chul Soon; Kim, Jong Oh

doi:10.1016/j.jconrel.2018.05.018

Cited by 165 publications

(130 citation statements)

References 51 publications

Supporting

Mentioning

130

Contrasting

Order By: Relevance

“…Similarly, Tregs mediate the immunosuppression by inhibiting the activation and expansion of effector T cells, and their downregulation could be ameliorated by the use of NCs. In particular, Tregs can be actively targeted by using their specific markers, such as glucocorticoid-induced Tumor Necrosis Factor Receptor-related protein (GITR), or neuropilin-1 receptor by binding of tLyp1 peptide [145,146]. However, this therapeutic strategy needs to be further validated because Tregs instability could be associated with the onset of autoimmune disorders [147].…”

Section: Nanoimmunology and New Targetsmentioning

confidence: 99%

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Salvioni

Rizzuto

Bertolini

et al. 2019

Cancers

160

138

View full text Add to dashboard Cite

Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.

show abstract

Section: Nanoimmunology and New Targetsmentioning

confidence: 99%

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Salvioni

Rizzuto

Bertolini

et al. 2019

Cancers

160

138

View full text Add to dashboard Cite

show abstract

“…Tregs are involved in the prevention of autoimmune disease via the establishment of immune tolerance against autoantigens. However, in cancer, Tregs can exert a suppressive effect on immune cells in the tumor [76]. For instance, anti-CTLA-4 is a checkpoint blockade that is utilized for the control of Tregs' activity in cancer immunotherapy.…”

Section: Nanoparticle-mediated Delivery Of Immunomodulatorsmentioning

confidence: 99%

Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy

Buabeid

Arafa

Murtaza

2020

Journal of Immunology Research

View full text Add to dashboard Cite

One of the standards for cancer treatment is cancer immunotherapy which treats both primary and metastasized tumors. Although cancer immunotherapeutics show better outcomes as compared with conventional approaches of cancer treatment, the currently used cancer immunotherapeutics have limited application in delivering cancer antigens to immune cells. Conversely, in solid tumors, tumor microenvironment suppresses the immune system leading to the evasion of anticancer immunity. Some promising attempts have been made to overcome these drawbacks by using different approaches, for instance, the use of biomaterial-based nanoparticles. Accordingly, various studies involving the application of nanoparticles in cancer immunotherapy have been discussed in this review article. This review not only describes the modes of cancer immunotherapy to reveal the importance of nanoparticles in this modality but also narrates nanoparticle-mediated delivery of cancer antigens and therapeutic supplements. Moreover, the impact of nanoparticles on the immunosuppressive behavior of tumor environment has been discussed. The last part of this review deals with cancer immunotherapy using a combination of traditional interventional oncology approach and image-guided local immunotherapy against cancer. According to recent studies, cancer therapy can potentially be improved through nanoparticle-based immunotherapy. In addition, drawbacks associated with the currently used cancer immunotherapeutics can be fixed by using nanoparticles.

show abstract

“…Therefore, the design of strategies targeted to deplete these cells employing antibodies [92] or drugs as Imatinib (IMT) [93] has led to significant enhancement in antitumoral immune responses, although they are not free of drawbacks as side toxicity or solubility problems. Ou et al have developed core-shell PLGA@lipid nanoparticles capable of delivering IMT in a selective and safe manner to Treg thanks to the surface decoration with a specific peptide tLyp1 [94]. This peptide presents high affinity by Neuropilin-1 (Nrp1) receptor, which is widely expressed on Treg but scarcely present in T effector cells.…”

Section: Nanoparticles To Enhance the Antitumoral Action Of Adaptive mentioning

confidence: 99%

“…Breast and colon cancer [88] Selective depletion T reg by targeting neuropilin-1 receptor with tLyp1 PLGA@lipid decorated with tLyp1 Imatinib combined with anti-CTLA-4 Melanoma [94] PTT by NIR to destroy T reg…”

Section: Nanoparticles To Enhance the Antitumoral Action Of Adaptive mentioning

confidence: 99%

Tumor Targeted Nanocarriers for Immunotherapy

Baeza

2020

Molecules

View full text Add to dashboard Cite

The paramount discovery of passive accumulation of nanoparticles in tumoral tissues triggered the development of a wide number of different nanoparticles capable of transporting therapeutic agents to tumoral tissues in a controlled and selective way. These nanocarriers have been endowed with important capacities such as stimuli-responsive properties, targeting abilities, or the capacity to be monitored by imaging techniques. However, after decades of intense research efforts, only a few nanomedicines have reached the market. The reasons for this disappointing outcome are varied, from the high tumor-type dependence of enhanced permeation and retention (EPR) effect to the poor penetration capacity of nanocarriers within the cancerous tissue, among others. The rapid nanoparticle clearance by immune cells, considered another important barrier, which compromises the efficacy of nanomedicines, would become an important ally in the fight against cancer. In the last years, the fine-tuned ability of immune cells to recognize and engulf nanoparticles have been exploited to deliver immunoregulating agents to specific immune cell populations selectively. In this work, the recent advances carried out in the development of nanocarriers capable of operating with immune and tumoral cells in order to orchestrate an efficient antitumoral response will be presented. The combination of nanoparticles and immunotherapy would deliver powerful weapons to the clinicians that offer safer and more efficient antitumoral treatments for the patients.

show abstract

Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy

Cited by 165 publications

References 51 publications

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy

Tumor Targeted Nanocarriers for Immunotherapy

Contact Info

Product

Resources

About